Mounjaro While Breastfeeding UK | Safety & Alternatives

Clinically Proven UK Registered Pharmacy

Mounjaro While Breastfeeding - Cheapest UK Price

Get the cheapest UK price on Mounjaro from £124.99 plus £20 off your first order with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Fast and discreet delivery
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off first order using code WEIGHTLOSSNEW
Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment
£145.00 From £124.99 £10 discount using discount code Weightlossnew
LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation

The Science Behind Mounjaro While Breastfeeding

Understanding mounjaro while breastfeeding UK safety is crucial for new mothers considering postpartum weight loss. Currently, Mounjaro (tirzepatide) is not recommended during breastfeeding due to insufficient safety data, but several clinically proven alternatives are available through UK-registered prescribers. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) explains the evidence and safer options for nursing mothers.

Why Mounjaro Is Not Recommended While Breastfeeding

Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that has not been adequately studied in breastfeeding women [1]. The MHRA and manufacturer guidelines state that it is unknown whether tirzepatide passes into human breast milk or what effects it might have on nursing infants.

Clinical trials specifically excluded pregnant and breastfeeding women, meaning no controlled data exists on infant exposure through breast milk [1]. Animal studies showed tirzepatide was present in the milk of lactating rats, though extrapolating animal data to humans requires caution [2].

The molecular weight of tirzepatide (approximately 4,813 Da) suggests limited transfer into breast milk, as larger molecules typically have reduced passage. However, without human pharmacokinetic studies, UK prescribers cannot confirm safety and must follow the precautionary principle outlined in MHRA guidance [3].

How Mounjaro Works in the Body

Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously [1]. This dual mechanism enhances insulin secretion, suppresses glucagon release, and significantly reduces appetite through central nervous system pathways.

In the SURMOUNT-1 trial, participants achieved an average body weight reduction of 20.9% over 72 weeks on the 15mg maintenance dose — the highest efficacy seen in any obesity medication trial to date [4]. The treatment works by slowing gastric emptying and increasing satiety signals to the brain.

These powerful metabolic effects raise important questions about breastfeeding safety. Any medication that significantly alters maternal metabolism and hormone signalling requires careful evaluation before use during lactation, particularly when infant exposure data is absent.

Pharmacokinetics and Breast Milk Transfer

Tirzepatide has a half-life of approximately 5 days, meaning it remains in the maternal system for extended periods [1]. Medications with longer half-lives have more opportunity to reach steady-state concentrations that could theoretically transfer into breast milk over time.

The protein-binding characteristics and lipophilicity of a medication influence milk transfer. While tirzepatide's large molecular structure may limit passage, the absence of lactation-specific studies means UK prescribers cannot quantify infant exposure risk with confidence [2][3].

MHRA and Clinical Guidelines for Breastfeeding Mothers

The Medicines and Healthcare products Regulatory Agency (MHRA) classifies medications based on available safety data for pregnancy and lactation. Mounjaro's Summary of Product Characteristics explicitly states that breastfeeding should be discontinued during treatment or the medication should not be used [3].

This guidance reflects the standard regulatory approach when human lactation data is unavailable. UK prescribers are bound by these recommendations and cannot prescribe Mounjaro to breastfeeding mothers unless the clinical benefit substantially outweighs the unknown risk — a threshold rarely met for weight management [3].

The British National Formulary (BNF) echoes this caution, noting that manufacturer advises avoiding use during breastfeeding. NHS guidance on postpartum weight loss similarly recommends waiting until after the breastfeeding period before considering prescription weight loss medications.

Treatment Mechanism Breastfeeding Status Post-Breastfeeding Price
Mounjaro (tirzepatide) Dual GIP/GLP-1 agonist Not recommended - insufficient data From £124.99
Wegovy (semaglutide) GLP-1 receptor agonist Not recommended - insufficient data From £69.00
Saxenda (liraglutide) GLP-1 receptor agonist Not recommended - insufficient data From £68.00
Orlistat Lipase inhibitor Minimal systemic absorption - prescriber assessment required From £32.00

Safer Weight Loss Options While Breastfeeding

For breastfeeding mothers seeking medically supported weight loss, several approaches have better-established safety profiles. Lifestyle interventions remain the first-line recommendation, with structured diet and exercise programmes showing effectiveness without medication-related risks.

Orlistat, available from £135.00 represents the only weight loss medication with some evidence in breastfeeding populations. This lipase inhibitor works locally in the gut to reduce fat absorption and has minimal systemic absorption, meaning negligible amounts enter breast milk [5]. However, it still requires individual prescriber assessment and may not be suitable for all nursing mothers.

Metformin, though not licensed specifically for weight loss in the UK, is sometimes prescribed off-label for women with PCOS or insulin resistance postpartum. Studies have shown minimal metformin transfer into breast milk, with infant exposure estimated at less than 1% of the maternal dose [6]. Any off-label use requires thorough discussion with a UK prescriber about risks and benefits.

When to Consider Prescription Weight Loss

Most UK prescribers recommend waiting until breastfeeding has concluded before starting GLP-1 receptor agonists like Mounjaro or Wegovy. If earlier intervention is medically necessary due to obesity-related complications, your prescriber will weigh the benefits of continuing breastfeeding against the need for treatment.

Partial weaning or transitioning to formula feeding may be discussed if weight loss medication is deemed clinically essential. These decisions are highly individual and should involve your GP, prescriber, and potentially a lactation consultant to ensure informed choice.

Alternative Treatments: Mounjaro vs Other Weight Loss Options

Understanding how Mounjaro compares to other weight loss treatments helps breastfeeding mothers plan their postpartum health journey. Wegovy (semaglutide) and Saxenda (liraglutide) are both GLP-1 receptor agonists with similar breastfeeding contraindications — neither has adequate safety data for nursing mothers [2][7].

Orlistat works through an entirely different mechanism by blocking dietary fat absorption in the intestine rather than acting systemically. Its minimal absorption means it has the lowest theoretical risk profile during breastfeeding, though evidence remains limited and prescriber assessment is essential [5].

Once you have finished breastfeeding, Mounjaro from £20 off first order using code WEIGHTLOSSNEW[4][8]. Your UK prescriber can help determine the optimal timing and treatment choice for your individual circumstances.

Planning Your Postpartum Weight Loss Journey

Evidence-based postpartum weight management begins with realistic expectations and safe timelines. The NHS recommends gradual weight loss of 0.5-1kg per week through balanced nutrition and physical activity, which supports continued breastfeeding without compromising milk supply.

If you are considering Mounjaro while breastfeeding UK options, the safest approach is to wait until lactation has concluded. Most women can then begin a clinical assessment for prescription weight loss treatments through a registered UK pharmacy like Cured Pharmacy, where transparent pricing starts from £135.00 for Mounjaro.

Our UK-registered clinical team provides free online consultations typically completed in under 3 minutes. You will receive an honest assessment of whether prescription weight loss medication is appropriate based on your medical history, current health status, and weight loss goals. All medications are genuine UK-licensed products dispensed by our GPhC-registered pharmacy with 100% discreet packaging and next-day delivery options.

Starting Your Assessment After Breastfeeding

When you are ready to explore prescription weight loss options post-breastfeeding, Cured Pharmacy offers a straightforward online consultation process. Our prescribers will review your postpartum health, any ongoing medical conditions, and current medications to determine the safest and most effective treatment.

Eligibility for Mounjaro typically requires a BMI of 30 or above, or 27 with weight-related health conditions such as hypertension or type 2 diabetes. Your prescriber will discuss realistic expectations, potential side effects, and the commitment required for successful outcomes with any GLP-1 treatment.

Scientific References

  1. Eli Lilly and Company. (2023). Mounjaro (tirzepatide) Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/14298
  2. Frias, J. P., et al. (2021). Efficacy and safety of tirzepatide in type 2 diabetes: A systematic review. Diabetes Therapy, 12(7), 1965-1986. https://doi.org/10.1007/s13300-021-01084-2
  3. Medicines and Healthcare products Regulatory Agency. (2023). Drug Safety Update: GLP-1 receptor agonists - guidance for prescribers. GOV.UK. Retrieved from https://www.gov.uk/drug-safety-update
  4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
  5. Hale, T. W. (2021). Medications and Mothers' Milk 2021 (19th ed.). Springer Publishing Company. ISBN: 978-0826147691
  6. Briggs, G. G., Freeman, R. K., & Yaffe, S. J. (2017). Drugs in Pregnancy and Lactation (11th ed.). Lippincott Williams & Wilkins. ISBN: 978-1496353313
  7. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799
  8. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication, particularly during breastfeeding or postpartum recovery. Mounjaro is not recommended for use while breastfeeding due to insufficient safety data.

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Can you take Mounjaro while breastfeeding in the UK?
No, Mounjaro is not recommended while breastfeeding due to insufficient safety data on tirzepatide transfer into breast milk and potential effects on nursing infants. UK prescribers follow MHRA guidance advising against use during lactation.
How long after stopping breastfeeding can I start Mounjaro?
You can typically begin a clinical assessment for Mounjaro immediately after fully stopping breastfeeding, as tirzepatide does not require a washout period. Your UK prescriber will confirm eligibility based on your individual health status and postpartum recovery.
Are there any weight loss injections safe while breastfeeding?
Currently, no GLP-1 receptor agonist injections (Mounjaro, Wegovy, Saxenda) have adequate safety data for breastfeeding mothers. Orlistat has minimal systemic absorption and may be considered in some cases, but requires individual prescriber assessment.
Does Mounjaro pass into breast milk?
It is unknown whether tirzepatide passes into human breast milk. Animal studies showed presence in rat milk, but no controlled human studies exist. The MHRA advises avoiding Mounjaro during breastfeeding due to this uncertainty.
What is the safest way to lose weight while breastfeeding UK?
The safest approach is gradual weight loss through balanced nutrition and moderate exercise, aiming for 0.5-1kg per week as recommended by NHS guidance. This supports continued milk production without medication-related risks to your infant.
Can I take Mounjaro if I am only breastfeeding occasionally?
Even with partial breastfeeding, Mounjaro is not recommended due to unknown infant exposure risks. If prescription weight loss is medically necessary, your UK prescriber will discuss whether transitioning fully to formula feeding is appropriate for your situation.
How effective is Mounjaro compared to other weight loss treatments after breastfeeding?
Mounjaro demonstrated the highest average weight reduction in clinical trials, with up to 20.9% body weight loss over 72 weeks in SURMOUNT-1. This exceeds semaglutide (14.9% in STEP trials) and liraglutide, making it a highly effective option once breastfeeding has concluded.
Where can I get Mounjaro in the UK after I stop breastfeeding?
Cured Pharmacy offers Mounjaro from £124.99 with a free online consultation completed in under 3 minutes. Our UK-registered prescribers assess eligibility and provide genuine UK-licensed medication with discreet next-day delivery once you have finished breastfeeding.
Is Mounjaro safe to use while breastfeeding in the UK?
Mounjaro is not recommended while breastfeeding as there is insufficient data on whether tirzepatide passes into breast milk or affects nursing infants. UK prescribers at Cured Pharmacy will assess your individual circumstances and advise on the safest weight loss options during breastfeeding.
When can I start Mounjaro after stopping breastfeeding?
You can typically start Mounjaro once you have completely stopped breastfeeding and your prescriber confirms it is safe to begin treatment. Cured Pharmacy's UK-registered clinicians will review your medical history and ensure Mounjaro is appropriate for you post-breastfeeding.
Are there alternatives to Mounjaro while breastfeeding UK mothers can use?
Weight loss medications are generally not recommended during breastfeeding, and lifestyle modifications are the preferred approach. Cured Pharmacy can provide guidance on safe weight management strategies while nursing and help you plan for Mounjaro treatment once breastfeeding has concluded.
How long does Mounjaro stay in your system after stopping treatment?
Mounjaro has a half-life of approximately 5 days, meaning it takes around 25 days for the medication to be mostly cleared from your system. If planning to breastfeed after Mounjaro use, discuss appropriate waiting periods with Cured Pharmacy's prescribers for personalised medical advice.
Can I get a prescription for Mounjaro while breastfeeding from Cured Pharmacy?
Cured Pharmacy's UK-registered prescribers cannot approve Mounjaro while you are actively breastfeeding due to safety concerns and lack of clinical data. However, they can assess your suitability for treatment once breastfeeding has stopped and provide the cheapest UK price from £124.99.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 17 July 2026